COMT INHIBITION IN PARKINSON’S DISEASE:
PAST REFLECTIONS, FUTURE DIRECTIONS

A satellite symposium at the 1st EAN Congress 2015

SUNDAY 21 JUNE 2015, 18:30–20:00
HALL A2, CITYCUBE, BERLIN, GERMANY
Dear Colleague,

I am delighted to invite you to the Bial satellite symposium COMT inhibition in Parkinson’s disease: past reflections, future directions.

For over 50 years, inhibition of catechol-O-methyltransferase (COMT) has been an attractive target for the management of wearing off effects in Parkinson’s disease. Even with currently available COMT inhibitors, treatment of motor complications remains a major unmet need. The development of more efficacious and safe compounds remains an important research goal.

During the symposium our faculty, composed of leading international authorities in the field, will review the pharmacology of COMT and the current and future role of COMT inhibitors in the management of Parkinson’s disease.

We look forward to meeting you in Berlin and exchanging views on this fascinating topic.

With warm regards,

Professor Andrew Lees

Organised and funded by